Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review
- PMID: 16879663
- DOI: 10.1111/j.1464-410X.2006.06290.x
Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review
Abstract
This review examines the role of nitric oxide (NO) as a neurotransmitter involved in the central and peripheral control of ejaculation, the methods of phosphodiesterase type 5 inhibitor (PDE5I) drug treatment studies for premature ejaculation (PE), the adherence of methods to the contemporary consensus of ideal PE drug trial design, the impact of methods on treatment outcomes and the role of PDE5Is in the treatment of PE. NO/cGMP transduction is involved in both the central and peripheral control of emission, but evidence for a direct central or peripheral effect of PDE5Is on ejaculation is speculative. Thirteen of the 14 studies reviewed failed to fulfil the evidence-based medicine criteria for ideal PE drug trial design. Limitations of the studies include inadequately defined study populations, the lack of a double-blind placebo-controlled study design, and the absence of consistent objective physiological measures or sensitive, validated outcome assessment instruments as study endpoints. The broad range of intravaginal ejaculatory latency time (IELT) fold-increases reported with PDE5Is, on-demand selective serotonin re-uptake inhibitor (SSRI) drugs, and combined PDE5I/on-demand SSRIs is testament to the unreliability of data and conclusions from methodologically flawed studies. The one study that fulfilled the evidence-based medicine criteria of an ideal clinical trial design reported that treatment with sildenafil failed to significantly increase baseline IELT, supporting our conclusion that there is no convincing evidence to support any role for PDE5Is in the treatment of men with lifelong PE and normal erectile function. However, there is limited evidence to support a potential role for PDE5Is alone or combined with daily or on-demand SSRIs in the treatment of acquired PE in men with comorbid erectile dysfunction. Further controlled studies adhering to the contemporary consensus of ideal clinical trial design are required to clarify the role of PDE5Is in this subgroup of men with acquired PE.
Similar articles
-
The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation.J Sex Med. 2011 Aug;8(8):2135-43. doi: 10.1111/j.1743-6109.2011.02401.x. J Sex Med. 2011. PMID: 21791006
-
The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.Eur Urol. 2007 Nov;52(5):1331-9. doi: 10.1016/j.eururo.2007.08.005. Epub 2007 Aug 17. Eur Urol. 2007. PMID: 17728050 Review.
-
Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.J Sex Med. 2011 Oct;8(10):2707-25. doi: 10.1111/j.1743-6109.2011.02386.x. Epub 2011 Jul 19. J Sex Med. 2011. PMID: 21771283 Review.
-
Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses.World J Urol. 2017 Dec;35(12):1817-1831. doi: 10.1007/s00345-017-2086-5. Epub 2017 Sep 14. World J Urol. 2017. PMID: 28913588 Review.
-
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.Urol Int. 2008;80(2):162-5. doi: 10.1159/000112607. Epub 2008 Mar 19. Urol Int. 2008. PMID: 18362486 Clinical Trial.
Cited by
-
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.Pharmaceuticals (Basel). 2023 Sep 6;16(9):1266. doi: 10.3390/ph16091266. Pharmaceuticals (Basel). 2023. PMID: 37765073 Free PMC article. Review.
-
Recreational use of oral erectile dysfunction medications among male physicians - A cross-sectional study.Urol Ann. 2023 Apr-Jun;15(2):148-157. doi: 10.4103/ua.ua_33_22. Epub 2023 Jan 16. Urol Ann. 2023. PMID: 37304517 Free PMC article.
-
Combinations of Freeze-Dried Amorphous Vardenafil Hydrochloride with Saccharides as a Way to Enhance Dissolution Rate and Permeability.Pharmaceuticals (Basel). 2021 May 11;14(5):453. doi: 10.3390/ph14050453. Pharmaceuticals (Basel). 2021. PMID: 34064796 Free PMC article.
-
Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity.Nat Rev Urol. 2021 Feb;18(2):115-127. doi: 10.1038/s41585-020-00417-1. Epub 2021 Jan 13. Nat Rev Urol. 2021. PMID: 33442049 Review.
-
Premature Ejaculation: Aetiology and Treatment Strategies.Med Sci (Basel). 2019 Oct 25;7(11):102. doi: 10.3390/medsci7110102. Med Sci (Basel). 2019. PMID: 31731516 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical